Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases will be acquired by Genentech, a member of the Roche Group. Jecure Therapeutics is focused on the discovery of novel therapeutics for the treatment of NASH and liver fibrosis.
Genentech will obtain full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors.
The utility of imaging biomarkers in NASH is the focus of several abstracts accepted for presentation at the American Association for the Study of Liver Disease’s The Liver Meeting® 2018, November 9-13, 2018 . Three abstracts – two selected as Posters of Distinction – highlight the use of Perspectum Diagnostics’ LiverMultiScan to identify, stratify and predict clinical outcomes of NASH.
The study, “Liver cT1 predicts clinical outcomes in patients with chronic liver disease, equivalent to liver biopsy,” demonstrates the performance of multiparametric MRI imaging in predicting clinical outcomes in liver disease. Research demonstrated further evidence that corrected T1 (cT1) can predict clinical outcomes in a larger cohort of patients with varying liver disease etiologies. Patients underwent multiparametric imaging (T1, T2* mapping (iron) and MR spectroscopy (fat). LiverMultiScan software was used to obtain cT1 maps of the liver and calculate the mean cT1 value from three regions of interest. cT1 significantly differentiated between all-cause mortality, liver-related mortality and liver event-free survival. Results showed that cT1 was as predictive for liver-related events as histology.
“Identifying high risk NASH patients using reliable, cost-effective non-invasive markers is critical for streamlining care pathways, enriching populations for clinical trials, and eventually prioritising patients for approved therapies. Multiparametric MRI, combining key phenotypic measurements in a single test, has the potential to fulfil a number of diagnostic purposes,” said Professor Jonathan Fallowfield, University of Edinburgh.
Professor Fallowfield is the clinical lead for the Innovate UK funded NASH Data Commons project
Joint studies will evaluate one or more of Pfizer’s investigational NASH therapies in combination with Novartis’s FXR agonist for the treatment of the progressive liver disease
Dr Tim Kendall is part of a collaborative team from across Scotland who are currently working on the SteatoSITE project.
SteatoSITE is a unified data system that allows sharing of genomic and clinical information from patients with NASH – the progressive form of non-alcoholic fatty liver disease (NAFLD) – making it more accessible for further research.
Tim explains the important role that digital pathology is playing in this ground-breaking project that could help develop new tests and treatments for patients with NAFLD, which affects 25% of Scots and currently has no cure.
What is digital pathology?
Pathology is often used to refer to the laboratory examination of samples of body tissue to make a diagnosis. The tissue gets cut into sections, put on a slide and looked at through a microscope.
With digital pathology, instead of using a microscope, you scan the slide and store the resulting image on a computer. You can move around the image and zoom in and out using a mouse rather than a microscope.
This is really useful for a number of reasons. If a doctor wanted a second opinion on a sample in the past, he would have to send a slide through the post. Using digital images allows doctors view the sample simultaneously, make notes on the image, collaborate and form an opinion together. It is also more secure – you can’t lose the sample because it is stored securely on a server and backed up.
What is the importance of digital pathology to the SteatoSITE project?
Let’s just say we’re looking at a sample of a fatty liver and trying to decide how much scarring is there. To describe this, I might say “some”, “a little”, or “a lot” of scarring – vague expressions that don’t mean much unless we turn them into numbers. So traditionally we score a sample using a published scale, but this isn’t particularly accurate either.
Computers, however, are very good at counting things. With a digital image, we can actually train the computer, using machine learning, to identify which pixels represent scar tissue. Once it has learned this, the computer can count the scar tissue pixels and give a percentage of the liver which is scarred – this is far more accurate and more statistically robust than assessing this by eye.
What is your role in the project?
This project involves pathologists in Glasgow, Aberdeen and Dundee as well as ourselves in Edinburgh. The samples are scanned here in Edinburgh and will then be uploaded to a platform which we can all get access to remotely. This will allow all of us to look at all 1000 samples in the project and score them in batches rather than relying on one person to do it all – it’s an incredibly efficient way of doing things.
I’ve also been involved in the identification of the tissue samples. Rather than going to electronic patient records to find patients with fatty liver disease, we are looking at pathological records, and selecting samples from four biorepositories across Scotland. We’ve been able to pull an anonymised list of any liver specimens reported in our system and find cases that refer to fatty liver disease. Rather than taking new samples from current patients, we’ve been able to use these samples from past patients which are routinely held anyway in case someone needs to be able to refer to them in future. It’s great to be able to use this resource for the public good.
What stage is the project at just now?
The pilot study using the first 59 samples is nearly complete – some analysis is still ongoing. The software to upload the scans from the pilot study and allow the whole team to view them is nearly ready. We will then sit down together ‘virtually’ and agree on how to score the samples, so when we move onto the full study, we’ll all be singing from the same hymn sheet.
We’ve already selected a lot of the remaining samples for the full study, so once we get ethical approval, the samples will be anonymised and entered into the study. This will be done in batches over the next 12 months. First, the samples will be stained within NHS Lothian, scanned and uploaded to the system and the team of pathologists will start to score them. Once scored, the data will be put into the SteatoSITE data commons, along with the images.
Sharing this information through SteatoSITE will be transformative for research efforts to better understand fatty liver disease. It will help to pinpoint patients at high risk of disease progression and will speed up the development of new therapies for this silent killer.
What project is currently taking up most of your time?
In February this year, we were awarded a £1.7M collaborative grant from Innovate UK for a ground-breaking project that could help develop new tests and treatments for patients with non-alcoholic fatty liver disease (NAFLD).
NAFLD is an accumulation of excess fat in the liver of people who drink little or no alcohol, and is strongly linked to type II diabetes and obesity. The progressive form of NAFLD, known as non-alcoholic steatohepatitis (NASH), can lead to liver fibrosis, liver cancer and premature death. Around 25% of the population are thought to have NAFLD, so it’s a massive issue.
To tackle the problem we need to get better at recognising the disease earlier and uncover some effective treatments, because currently there is no approved therapy.
The grant funding is being used to develop a Data Commons, known as SteatoSITE. A Data Commons is a unified data system that allows sharing of genomic and clinical information from patients with NASH, making it more accessible for further research.
SteatoSITE will be the world’s first Data Commons for NASH, and when complete it will lead to a deeper understanding of which tests and treatments are most effective for individual patients.
What stage is the project at?
We’re currently at the pilot stage. For SMS-IC, this involves preparing “libraries” from ribonucleic acid (RNA) that has been extracted from 59 samples of liver tissue from patients with NASH, which have come from the biorepositories in Glasgow and Edinburgh. These samples are a mixture of tissue taken from surgery and from fine needle biopsies.
How has this process been going?
The tissue samples we have are known as FFPE (Formalin-Fixed Paraffin-Embedded) samples – this means they are not fresh, they have been preserved. This can present some challenges as the preservation process can result in degradation of the RNA, resulting in shorter fragments than you might get from fresh tissue. Longer fragments generally give better results. Because of our expertise in working with difficult samples, we are in the process of tweaking our library process to overcome the issues associated with FFPE samples.
The samples have had a lot of analysis done on them to allow us to see how intact the RNA is – we use a metric called DV200, which tells us the percentage of fragments which are less than 200 bases in length, as we know we won’t get great results from these. The best samples have about 70% of their RNA fragments above 200 bases in length. Anything with less than 30% of fragments above 200 bases in length is likely to be too degraded to be useful.
What will this pilot study achieve?
The pilot study will help us set our acceptance criteria for samples for the overall project. If we know that samples that have a certain level of degradation don’t produce good libraries, then it’s a waste of time including them. However, we want as many libraries as possible to make sure the cohort for the overall study is as big as it can be. The good news is that most of the samples in the pilot are giving us good yields, which is really encouraging.
What’s next for the project?
We will transport the pilot libraries to Edinburgh Genomics, who are a global leader in DNA sequencing and genomics based at the University of Edinburgh. They will carry out the sequencing part of the project – this is where they will look at the genomic information in each of the samples.
Once they’ve done that, we’ll then get feedback on the quality of the sequencing, which will tell us if we’re ready to get started on the full-blown project, which will consist of 1000 tissue samples. There will be a lot of data to come out of that! This new data will be combined with information from digital pathology, clinical and electronic health records. It will help to pinpoint patients at high risk of disease progression and will speed up the development of new therapies.
What strengths are SMS-IC bringing to this project?
Firstly, we can access ethically sourced tissue samples from biorepositories right across Scotland. We have capabilities to prepare libraries which are suitable for sequencing, including working successfully with degraded FFPE samples. We can also build successful relationships and collaborations with world-class teams such as Edinburgh Genomics.
If you think we could work on a project together, please get in touch with us on admin@stratmed.co.uk
Gemphire Therapeutics is halting its phase 2a trial in pediatric nonalcoholic fatty liver disease (NAFLD) because some patients’ disease got worse.
This report on fiercebiotech describes how an increase in liver fat was deemed an unexpected problem by the trial investigator. It was an unexpected consistent pattern of worsening of the disease, rather than improvement. The investigators believed this effect was due to the drug, and created risk to the patients,
The trial started early this year, patients were dosed with 300 mg of gemcabene daily. The primary endpoint was a change in serum alanine transaminase (ALT), which is an an enzyme biomarker of liver function, after 12 weeks of treatment. Secondary endpoints included a change in hepatic steatosis, the buildup of fat in the liver.
The first three patients that completed 12 weeks of treatment had an increase in liver fat content, as well as elevated ALT levels.
The Problem. NASH stands for non-alcoholic steatohepatitis. It’s the worst form of non-alcoholic fatty liver disease (NAFLD). It’s where abnormal fat builds up in the liver. Over time NASH can lead to too much scarring in the liver (fibrosis). This is the body’s natural response to injury but it can lead to liver cirrhosis, liver cancer and premature death.
NAFLD is a silent epidemic. At the moment, we just don’t have any approved medical treatments – but we’re working on a project which we hope will change this.
Remarkably, best estimates say that 25% of the world’s population has NAFLD. It’s strongly linked to obesity and type-2 diabetes. Chronic liver disease (increasingly due to NAFLD) is now the 3rd most common cause of premature death in the UK. By 2020 we expect that NASH will be the main reason for liver transplants.
Spotting the signs of the disease early and having effective treatment is urgently needed to cut deaths. This disease has an economic burden too – in Germany, France, Italy, and the UK combined, there are around 52 million people with NAFLD, costing €35 billion every year.
So, what can be done? I’m the Chief Investigator of a team, managed by the Stratified Medicine Scotland Innovation Centre and led by industry partners Eagle Genomics. We’re developing a ground-breaking project to develop new tests and treatments for people with NASH. The project also has the Universities of Edinburgh and Glasgow and NHS Scotland as partners. The team recently got a £1.7 million research grant from Innovate UK (the UK’s innovation agency) to develop a Data Commons for NASH – a world first.
A Data Commons brings together data, storage and computing systems. It’s a widely used tool for analysing and sharing data to create a resource for a wide range of users including the research community and clinicians – and potentially patients and charities too. As more health data is added, our NASH Data Commons will evolve into a smarter, more comprehensive knowledge system that will be used to make new discoveries to understand and treat this disease better. It will help us to develop and validate new tests for NASH, and to identify patients who will get the most benefit from new therapies. We’re calling it SteatoSITE.
Where do you fit in? This exciting project (and future research following on from it) will benefit hugely from members of the public getting their say. The NHS and Government want to prioritise this type of digital health and ways of analysing it (for example, using artificial intelligence), but there are ethical, legal, and social implications about accessing, storing and using people’s health data. We want to get people’s views on the way we’ll use health data and our methods of keeping it secure. We also want help to find the best ways to publicise our research and to make sure that users with varying levels of expertise can all make best use of SteatoSITE.
We want to get a small (3-5 people) non-expert focus group together face-to-face to talk about the broad aspects of the project (for about 2 hours). Then we plan to get the group back together after 1 year and also at the end of the 2-year project to discuss progress, issues arising, and next steps. Interested? We’ll give you back any reasonable travel expenses and you’ll also get a £20 Amazon voucher to say thank you.
